NOVT
Get informed when a big investor buys or sells
+ FollowOvervalued by 79.6% based on the discounted cash flow analysis.
| Market cap | $5.17 Billion |
|---|---|
| Enterprise Value | $4.74 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.47 |
| Beta | 1.68 |
| Outstanding Shares | 41,009,000 |
| P/E Ratio | 91.35 |
|---|---|
| PEG | 51.07 |
| Price to Sales | 6.28 |
| Price to Book Ratio | 4.03 |
| Enterprise Value to Revenue | 4.6 |
| Enterprise Value to EBIT | 46.73 |
| Enterprise Value to Net Income | 76 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.17 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 19.5831▲ 1558.86% |
|---|---|
| Total Calls | 125,200▲ 14.55% |
| Total Puts | 2,451,800▲ 461.57% |
Holdings and activity of institutional investors.
| Ownership % | 112.04%▲ 1.34% |
|---|---|
| Total Invested | $7.34B▲ 53.60% |
| Investors Holding | 398▲ 56.00% |
No data
Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers ('OEMs') a competitive advantage. Novanta combines deep proprietary technology expertise and com...